G
Gaurav Singal
Researcher at Foundation Medicine
Publications - 50
Citations - 2198
Gaurav Singal is an academic researcher from Foundation Medicine. The author has contributed to research in topics: Computer science & Cancer. The author has an hindex of 12, co-authored 33 publications receiving 1274 citations. Previous affiliations of Gaurav Singal include Brigham and Women's Hospital & Beth Israel Deaconess Medical Center.
Papers
More filters
Journal ArticleDOI
STK11/LKB1 Mutations and PD-1 Inhibitor Resistance in KRAS-Mutant Lung Adenocarcinoma.
Ferdinandos Skoulidis,Michael E. Goldberg,Danielle Greenawalt,Matthew D. Hellmann,Mark M. Awad,Justin F. Gainor,Alexa B. Schrock,Ryan J. Hartmaier,Sally E. Trabucco,Siraj M. Ali,Julia A. Elvin,Gaurav Singal,Jeffrey S. Ross,David Fabrizio,Péter Szabó,Han Chang,Ariella Sasson,Sujaya Srinivasan,Stefan Kirov,Joseph D. Szustakowski,Patrik Vitazka,Robin Edwards,Jose A. Bufill,Neelesh Sharma,Sai-Hong Ignatius Ou,Nir Peled,Nir Peled,David R. Spigel,Hira Rizvi,Elizabeth Jimenez Aguilar,Brett W. Carter,Jeremy J. Erasmus,Darragh Halpenny,Andrew J. Plodkowski,Niamh Long,Mizuki Nishino,Warren Denning,Ana Galan-Cobo,Haifa Hamdi,Taghreed Hirz,Pan Tong,Jing Wang,Jaime Rodriguez-Canales,Pamela Villalobos,Edwin Roger Parra,Neda Kalhor,Lynette M. Sholl,Jennifer L. Sauter,Achim A. Jungbluth,Mari Mino-Kenudson,Roxana Azimi,Yasir Elamin,Jianjun Zhang,Giulia Costanza Leonardi,Fei Jiang,Fei Jiang,Kwok-Kin Wong,J. Jack Lee,Vassiliki A. Papadimitrakopoulou,Ignacio I. Wistuba,Vincent A. Miller,Garrett M. Frampton,Jedd D. Wolchok,Alice T. Shaw,Pasi A. Jänne,Philip J. Stephens,Charles M. Rudin,William J. Geese,Lee A. Albacker,John V. Heymach +69 more
TL;DR: Genomic profiling may enhance the predictive utility of PD-L1 expression and tumor mutation burden and facilitate establishment of personalized combination immunotherapy approaches for genomically defined LUAC subsets.
Journal ArticleDOI
Association of Patient Characteristics and Tumor Genomics With Clinical Outcomes Among Patients With Non-Small Cell Lung Cancer Using a Clinicogenomic Database
Gaurav Singal,Gaurav Singal,Peter Miller,Vineeta Agarwala,Gerald Li,Gaurav Kaushik,Daniel Backenroth,Anala Gossai,Garrett M. Frampton,Aracelis Z. Torres,Erik M. Lehnert,David Bourque,Claire O'Connell,Bryan Bowser,Thomas Caron,Ezra Baydur,Kathi Seidl-Rathkopf,Ivan Ivanov,Garrett Alpha-Cobb,Ameet Guria,Jie He,Shannon Frank,Allen C. Nunnally,Mark Bailey,Ann Jaskiw,Dana Feuchtbaum,Nathan C. Nussbaum,Amy P. Abernethy,Vincent A. Miller +28 more
TL;DR: Whether a database that combines EHR-derived clinical data with CGP can identify and extend associations in non–small cell lung cancer (NSCLC) can be identified and extended, and how this approach may accelerate precision medicine.
Journal ArticleDOI
Lateralization of face processing in the human brain
TL;DR: The authors found that activation patterns in the left fusiform gyrus correlate with image-level face-semblance, while those in the right correlate with categorical face/non-face judgements.
Journal Article
Lateralization of face processing in the human brain
TL;DR: The results provide important clues regarding the functional architecture of face processing, suggesting that the left hemisphere is involved in processing ‘low-level’ face semblance, and perhaps is a precursor to categorical ‘deep’ analyses on the right.
Journal ArticleDOI
Somatic HLA Class I Loss Is a Widespread Mechanism of Immune Evasion Which Refines the Use of Tumor Mutational Burden as a Biomarker of Checkpoint Inhibitor Response.
Meagan Montesion,Karthikeyan Murugesan,Dexter X. Jin,Radwa Sharaf,Nora Sanchez,Ameet Guria,Max Minker,Gerald Li,Virginia Fisher,Ethan Sokol,Dean Pavlick,Jay A. Moore,Alan Braly,Gaurav Singal,David Fabrizio,Leah Comment,Naiyer A. Rizvi,Brian M. Alexander,Garrett M. Frampton,Priti Hegde,Lee A. Albacker +20 more
TL;DR: In ICI treated non-squamous non-small cell lung cancer patients, HLA-I LOH was a significant negative predictor of overall survival, and survival prediction improved when combined with TMB, suggesting TMB with HLA to better identify patients likely to benefit from ICIs.